121 related articles for article (PubMed ID: 37690543)
21. Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma.
Chapin BF; Delacroix SE; Culp SH; Nogueras Gonzalez GM; Tannir NM; Jonasch E; Tamboli P; Wood CG
Eur Urol; 2011 Nov; 60(5):964-71. PubMed ID: 21621907
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of the Glasgow Prognostic Score for patients with metastatic renal cell carcinoma treated by cytoreductive nephrectomy.
Fukuda H; Takagi T; Kondo T; Yoshida K; Shimizu S; Nagashima Y; Tanabe K
Int J Clin Oncol; 2018 Jun; 23(3):539-546. PubMed ID: 29302841
[TBL] [Abstract][Full Text] [Related]
23. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
[TBL] [Abstract][Full Text] [Related]
24. Oncologic Outcomes of Cytoreductive Nephrectomy in Synchronous Metastatic Renal-Cell Carcinoma: A Single-Center Experience.
Choi CI; Kang M; Sung HH; Jeon HG; Jeong BC; Jeon SS; Lee HM; Seo SIL
Clin Genitourin Cancer; 2018 Dec; 16(6):e1189-e1199. PubMed ID: 30262447
[TBL] [Abstract][Full Text] [Related]
25. Cytoreductive nephrectomy in metastatic renal cell carcinoma: outcome of patients treated with a multidisciplinary, algorithm-driven approach.
Liu WK; Lam JM; Butters T; Grant M; Jackson-Spence F; Bex A; Powles T; Szabados B
World J Urol; 2020 Dec; 38(12):3199-3205. PubMed ID: 32128610
[TBL] [Abstract][Full Text] [Related]
26. Long-term outcomes after cytoreductive nephrectomy and thrombectomy of patients with metastatic renal cell carcinoma with venous tumor thrombus: a retrospective study from a large Chinese center.
Chen K; Liu Z; Li Y; Zhao X; Zhang Y; Bi H; Wang G; Liu C; Tian X; Zhang H; Ma L; Zhang S
World J Surg Oncol; 2023 Jun; 21(1):170. PubMed ID: 37280590
[TBL] [Abstract][Full Text] [Related]
27. The independent oncological role for cytoreductive nephrectomy in metastatic renal cell carcinoma: Prognostic features in the era of targeted therapies.
Claeys T; Lumen N; Kumps C; Praet M; De Meerleer G; Rottey S; Ost P; Devisschere P; Villeirs G; Fonteyne V; Decaestecker K
Urol Oncol; 2017 Apr; 35(4):152.e13-152.e22. PubMed ID: 28153420
[TBL] [Abstract][Full Text] [Related]
28. Cytoreductive nephrectomy for metastatic renal cell carcinoma: a population-based analysis of perioperative outcomes according to clinical stage.
Takagi T; Sugihara T; Yasunaga H; Horiguchi H; Fushimi K; Kondo T; Homma Y; Tanabe K
Int J Urol; 2014 Aug; 21(8):770-5. PubMed ID: 24712555
[TBL] [Abstract][Full Text] [Related]
29. Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma: How to Apply New Evidence in Clinical Practice.
Soares A; Maia MC; Vidigal F; Marques Monteiro FS
Oncology; 2020; 98(1):1-9. PubMed ID: 31514196
[TBL] [Abstract][Full Text] [Related]
30. Outcomes following cytoreductive nephrectomy without immediate postoperative systemic therapy for patients with synchronous metastatic renal cell carcinoma.
Andrews JR; Lohse CM; Boorjian SA; Leibovich BC; Thompson H; Costello BA; Bhindi B
Urol Oncol; 2022 Apr; 40(4):166.e1-166.e8. PubMed ID: 35168879
[TBL] [Abstract][Full Text] [Related]
31. Minimally invasive cytoreductive nephrectomy: a multi-institutional experience.
Nunez Bragayrac L; Hoffmeyer J; Abbotoy D; Attwood K; Kauffman E; Spiess P; Wagner A; Schwaab T
World J Urol; 2016 Dec; 34(12):1651-1656. PubMed ID: 27084776
[TBL] [Abstract][Full Text] [Related]
32. Cytoreductive Nephrectomy in Metastatic Patients with Signs or Symptoms: Implications for Renal Cell Carcinoma Guidelines.
Larcher A; Fallara G; Rosiello G; Re C; Baiamonte G; Agnesi S; Cignoli D; Colandrea G; Basile G; Briganti A; Salonia A; Bertini R; Montorsi F; Capitanio U
Eur Urol; 2020 Sep; 78(3):321-326. PubMed ID: 32507335
[TBL] [Abstract][Full Text] [Related]
33. The Role of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: A Real-World Multi-Institutional Analysis.
Ghatalia P; Handorf EA; Geynisman DM; Deng M; Zibelman MR; Abbosh P; Anari F; Greenberg RE; Viterbo R; Chen D; Smaldone MC; Kutikov A; Uzzo RG
J Urol; 2022 Jul; 208(1):71-79. PubMed ID: 35212574
[TBL] [Abstract][Full Text] [Related]
34. Deferred Cytoreductive Nephrectomy Following Presurgical Vascular Endothelial Growth Factor Receptor-targeted Therapy in Patients with Primary Metastatic Clear Cell Renal Cell Carcinoma: A Pooled Analysis of Prospective Trial Data.
de Bruijn R; Wimalasingham A; Szabados B; Stewart GD; Welsh SJ; Kuusk T; Blank C; Haanen J; Klatte T; Staehler M; Powles T; Bex A
Eur Urol Oncol; 2020 Apr; 3(2):168-173. PubMed ID: 31956080
[TBL] [Abstract][Full Text] [Related]
35. The Association Between Small Primary Tumor Size and Prognosis in Metastatic Renal Cell Carcinoma: Insights from Two Independent Cohorts of Patients Who Underwent Cytoreductive Nephrectomy.
DiNatale RG; Xie W; Becerra MF; Silagy AW; Attalla K; Sanchez A; Mano R; Marcon J; Blum KA; Benfante NE; Voss MH; Motzer RJ; Coleman J; Choueiri TK; Reznik E; Russo P; Heng DYC; Hakimi AA
Eur Urol Oncol; 2020 Feb; 3(1):47-56. PubMed ID: 31735646
[TBL] [Abstract][Full Text] [Related]
36. Postoperative Changes in Skeletal Muscle Mass Predict Survival of Patients With Metastatic Renal Cell Carcinoma Undergoing Cytoreductive Nephrectomy.
Fukushima H; Nakanishi Y; Kataoka M; Tobisu KI; Koga F
Clin Genitourin Cancer; 2017 Apr; 15(2):e229-e238. PubMed ID: 27601279
[TBL] [Abstract][Full Text] [Related]
37. Impact of Primary Tumor Size on Prognosis in Patients With Metastatic Renal Cell Carcinoma Receiving Cytoreductive Nephrectomy: A Population Study of a Chinese Center and the US SEER Database.
Jiang W; Shou J; Shi H; Wen L; Zhang H; Zheng S; Li C; Ma J
Technol Cancer Res Treat; 2021; 20():15330338211019507. PubMed ID: 34032149
[TBL] [Abstract][Full Text] [Related]
38. Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma.
Bhindi B; Graham J; Wells JC; Bakouny Z; Donskov F; Fraccon A; Pasini F; Lee JL; Basappa NS; Hansen A; Kollmannsberger CK; Kanesvaran R; Yuasa T; Ernst DS; Srinivas S; Rini BI; Bowman I; Pal SK; Choueiri TK; Heng DYC
Eur Urol; 2020 Oct; 78(4):615-623. PubMed ID: 32362493
[TBL] [Abstract][Full Text] [Related]
39. Optimizing patient selection for cytoreductive nephrectomy based on outcomes in the contemporary era of systemic therapy.
McIntosh AG; Umbreit EC; Holland LC; Gu C; Tannir NM; Matin SF; Karam JA; Culp SH; Wood CG
Cancer; 2020 Sep; 126(17):3950-3960. PubMed ID: 32515845
[TBL] [Abstract][Full Text] [Related]
40. Surgical outcomes and complications associated with presurgical tyrosine kinase inhibition for advanced renal cell carcinoma (RCC).
Harshman LC; Yu RJ; Allen GI; Srinivas S; Gill HS; Chung BI
Urol Oncol; 2013 Apr; 31(3):379-85. PubMed ID: 21353796
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]